3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Rectal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Heart Failure
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Endometrial Adenocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Carcinoma
1
Interventions
Control Groups
2
Atorvastatin
2
sacubitril and valsartan sodium hydrate drug combination
1
pertuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
dapagliflozin
1
candesartan
1
Trastuzumab
1
Sodium Chloride
1
Simendan
1
Pyruvic Acid
1
Population Groups
1
Ogivri
1
Metoprolol
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Eplerenone
1
Carvedilol
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Heart Failure
×
Ogivri
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled